Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICAM1 | P05362 | 1/20 | 0.38 |
| ▸ | SELE | P16581 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TACR1 | P25103 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 5/20 | 0.34 |
| ▸ | CA2 | P00918 | 5/20 | 0.34 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16727109 | 0.89 | ICAM1 (0.38) | ICAM1SELEKDM4CCREBBPRAB9A | |
| SCHEMBL30834549 | 0.89 | ICAM1 (0.38) | ICAM1SELEKDM4CCREBBPRAB9A | |
| SCHEMBL22165283 | 0.85 | ICAM1 (0.39) | ICAM1SELEKDM4CCREBBPRAB9A | |
| SCHEMBL15278408 | 0.85 | ICAM1 (0.39) | ICAM1SELEKDM4CCREBBPRAB9A | |
| SCHEMBL92906 | 0.84 | DRD4 (0.47) | ICAM1SELEKDM4CCREBBPRAB9A | |
| SCHEMBL93016 | 0.83 | SMN1; SMN2 (0.47) | ICAM1SELEKDM4CCREBBPRAB9A | |
| SCHEMBL4680154 | 0.82 | ICAM1 (0.39) | ICAM1SELEKDM4CCREBBPRAB9A | |
| SCHEMBL23647767 | 0.82 | ICAM1 (0.39) | ICAM1SELEKDM4CCREBBPRAB9A | |
| SCHEMBL3078260 | 0.81 | ICAM1 (0.40) | ICAM1SELEKDM4CCREBBPRAB9A | |
| SCHEMBL1704760 | 0.81 | L3MBTL1 (0.40) | ICAM1SELEKDM4CCREBBPRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2828243-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9499538-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499538-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499538-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150105403-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150105403-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150105403-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| EP-2828243-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Seragon Pharmaceuticals, Inc. (US) | 2015-01-28 | — | — | EP | disclosed |
| WO-2013142266-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013142266-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| CN-1036919-C | Pyrazole condensed ring derivatives, method of manufacturing the same, and androgen inhibitor | OTSUKA PHARMA CO LTD (JP) | 1998-01-07 | — | — | CN | disclosed |
| US-5516777-A | PROSTATE CANCER THERAPY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-14 | — | — | US | disclosed |
| US-5409928-A | Prostate diseases, alopecia | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-04-25 | — | — | US | disclosed |
| CN-1089609-A | Pyrazole-fused ring derivatives, its manufacture method and male hormone inhibitor | OTSUKA PHARMA CO LTD (JP) | 1994-07-20 | — | — | CN | disclosed |
| EP-0594149-A2 | Condensed pyrazole derivatives, method of manufacturing the same, and androgen inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105403-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | ICAM1 2241/4885SELE 1055/4885KDM4C 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.